Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab consolidation in locally advanced nasopharyngeal carcinoma
NCT04227509Phase 2Completed
- Sponsor
- Seoul National University Hospital
- Start
- Jun 2020
- Primary completion
- Aug 2024
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised trial of pembrolizumab in nasopharyngeal carcinoma (NPC) (2 arms), sponsored by Seoul National University Hospital. Primary endpoint: Progression-Free Survival Rate at 3 years. Started Jun 2020; status: completed.
02
Drugs
03
Conditions
nasopharyngeal carcinoma (NPC)
Beyond the preview
Go deeper on NCT04227509.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04227509.